Cargando…

Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction

BACKGROUND: We investigated the effects of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration focusing on its involvement in tubulo-interstitial disorders in diabetic kidney. METHODS: Enrolled patients with diabetic kidney disease received a mean dose of 52.3 mg of an SGLT2i (ipraglifl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Saeko, Takayanagi, Kaori, Shimizu, Taisuke, Kanozawa, Koichi, Iwashita, Takatsugu, Hasegawa, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356509/
https://www.ncbi.nlm.nih.gov/pubmed/35933386
http://dx.doi.org/10.1186/s40001-022-00737-5
_version_ 1784763534617346048
author Sato, Saeko
Takayanagi, Kaori
Shimizu, Taisuke
Kanozawa, Koichi
Iwashita, Takatsugu
Hasegawa, Hajime
author_facet Sato, Saeko
Takayanagi, Kaori
Shimizu, Taisuke
Kanozawa, Koichi
Iwashita, Takatsugu
Hasegawa, Hajime
author_sort Sato, Saeko
collection PubMed
description BACKGROUND: We investigated the effects of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration focusing on its involvement in tubulo-interstitial disorders in diabetic kidney. METHODS: Enrolled patients with diabetic kidney disease received a mean dose of 52.3 mg of an SGLT2i (ipragliflozin) daily. Blood and urine were sampled at 0, 1, and 12 months (M). RESULTS: Non-renal-dysfunction patients (NRD: baseline eGFR ≥ 60 mL/min/1.73 m(2), n = 12) and renal-dysfunction patients (RD: baseline eGFR < 60 mL/min/1.73 m(2), n = 9) were analyzed separately. The median urine albumin-to-Cr ratio (ACR) was significantly decreased at 1 M in both groups (NRD: 163.1 at 0 M vs 118.5 mg/g Cr at 1 M, RD: 325.2 at 0 M vs 136.0 mg/g Cr at 1 M). In the RD, but not the NRD group, reduction of urine monocyte chemotactic protein-1 (MCP-1) by SGLT2i showed a significant difference between high-responders (HR: − 25.7 ± 11.4%) and low-responders (LR: 59.2 ± 17.0%), defined by ACR reduction at 1 M. Univariate analysis showed a significant correlation between the reduction of ACR and MCP-1 (R = 0.683, p = 0.042) in RD. CONCLUSION: SGLT2i exerted an anti-albuminuric effect regardless of the presence/absence of renal dysfunction. However, the anti-albuminuric effect of SGLT2i in patients with renal dysfunction appears more closely associated with amelioration of tubulo-interstitial disorders compared to patients without renal dysfunction.
format Online
Article
Text
id pubmed-9356509
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93565092022-08-07 Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction Sato, Saeko Takayanagi, Kaori Shimizu, Taisuke Kanozawa, Koichi Iwashita, Takatsugu Hasegawa, Hajime Eur J Med Res Research BACKGROUND: We investigated the effects of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration focusing on its involvement in tubulo-interstitial disorders in diabetic kidney. METHODS: Enrolled patients with diabetic kidney disease received a mean dose of 52.3 mg of an SGLT2i (ipragliflozin) daily. Blood and urine were sampled at 0, 1, and 12 months (M). RESULTS: Non-renal-dysfunction patients (NRD: baseline eGFR ≥ 60 mL/min/1.73 m(2), n = 12) and renal-dysfunction patients (RD: baseline eGFR < 60 mL/min/1.73 m(2), n = 9) were analyzed separately. The median urine albumin-to-Cr ratio (ACR) was significantly decreased at 1 M in both groups (NRD: 163.1 at 0 M vs 118.5 mg/g Cr at 1 M, RD: 325.2 at 0 M vs 136.0 mg/g Cr at 1 M). In the RD, but not the NRD group, reduction of urine monocyte chemotactic protein-1 (MCP-1) by SGLT2i showed a significant difference between high-responders (HR: − 25.7 ± 11.4%) and low-responders (LR: 59.2 ± 17.0%), defined by ACR reduction at 1 M. Univariate analysis showed a significant correlation between the reduction of ACR and MCP-1 (R = 0.683, p = 0.042) in RD. CONCLUSION: SGLT2i exerted an anti-albuminuric effect regardless of the presence/absence of renal dysfunction. However, the anti-albuminuric effect of SGLT2i in patients with renal dysfunction appears more closely associated with amelioration of tubulo-interstitial disorders compared to patients without renal dysfunction. BioMed Central 2022-08-06 /pmc/articles/PMC9356509/ /pubmed/35933386 http://dx.doi.org/10.1186/s40001-022-00737-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sato, Saeko
Takayanagi, Kaori
Shimizu, Taisuke
Kanozawa, Koichi
Iwashita, Takatsugu
Hasegawa, Hajime
Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title_full Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title_fullStr Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title_full_unstemmed Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title_short Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
title_sort correlation between albuminuria and interstitial injury marker reductions associated with sglt2 inhibitor treatment in diabetic patients with renal dysfunction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356509/
https://www.ncbi.nlm.nih.gov/pubmed/35933386
http://dx.doi.org/10.1186/s40001-022-00737-5
work_keys_str_mv AT satosaeko correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction
AT takayanagikaori correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction
AT shimizutaisuke correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction
AT kanozawakoichi correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction
AT iwashitatakatsugu correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction
AT hasegawahajime correlationbetweenalbuminuriaandinterstitialinjurymarkerreductionsassociatedwithsglt2inhibitortreatmentindiabeticpatientswithrenaldysfunction